

The following planning committee members and faculty reported relevant financial relationships.

| | | |
|----------|--------------------|--|
| Erik | Alexander | Roche Diagnostics: Study data Monitor [xRelationship Ended]; Veracyte Inc: Consultant |
| Julia | Baran | Rare Thyroid Therapeutics International AB: Consultant [x Relationship Ended] |
| Giuseppe | Barbesino | Horizon Pharma: advisor [xRelationship Ended]; Immunovant: advisor; Sention Therapeutics: consultant [xRelationship Ended]; Momenta: consultant: [xRelationship Ended]; |
| Vahe | Bedian | Viridian Therapeutics: Employee; Dianthus Therapeutics: Consultant; Remedy Plan: Advisory Board member; MindImmune Therapeutics: Consultant; Astria Therapeutics: Consultant |
| Antonio | Bianco | Abbvie: Consultant; Synthonics: Consultant; Thyron: Consultant; Sention: Consultant; Acella Pharmaceuticals: Consultant |
| Eve | Bloomgarden | Horizon Therapeutics: Speaker |
| Kristien | Boelaert | Lilly: Advisory Board Member: use of Selpercatnib |
| Kristien | Boelaert | Lilly: Advisory Board Member: use of Selpercatnib |
| Ronald | Brazg | Abbie: Reserch Funding; EH (?): Reserch Funding; Sention: Research Funding; Medtronic: Research funding |
| Naifa | Busaidy | Novartis: Research [xRelationship Ended]; Eisai: Advisory Board [xRelationship Ended]; Exelixis: Consultant [xRelationship Ended] |
| Maria | Cabanillas | Genentech: Grant funding; Merck: Grant funding; Exelixis: Consultant; Bayer: Consultant |
| Maria | Cabanillas | Genentech: Grant funding; Merck: Grant funding; Exelixis: Consultant; Bayer: Consultant |
| Maria | Cabanillas | Genentech: Grant funding; Merck: Grant funding; Exelixis: Consultant; Bayer: Consultant |
| Raquel | Cano | ABBOTT: Speaker; Valentech: Speaker; Servier: Speaker |
| Anne | Cappola | Xyone Therapeutics: Consultant |
| Marco | Centanni | IBSA CH: Meeting honorarium, travel reimbursement |
| Sophie | Dream | Roche: Speaker Fee, Advisory Board; Neopharm: Speaker Fee; CTS Israil: Speaker Fee, Advisory Board |
| Leonidas | Duntas | Merck KgGA: Speaker at an educational meeting; Berlin Chemie: Speaker at an educational meeting [xRelationship Ended] |
| James | Fagin | Kura Oncology: Royalties, Patent Beneficiary |
| Sky | Ferrara | Autobahn Therapeutics:Patent Royalties |
| Natalia | Genere | Medscape - Endocrinology Section: Independent contractor/consultant-developed educational material |
| Natalia | Genere | Medscape - Endocrinology Section: Independent contractor/consultant-developed educational material |
| Whitney | Goldner | Roche: Site PI of multicenter study; Siemens: Site PI of multicenter study |
| Julien | Hadoux | Lilly: Consultant; Roche: Consultant; IPSEN: Consultant [xRelationship Ended]; Pharma Mar: Consultant [xRelationship Ended]; AAA: Consultant [xRelationship Ended]. |
| Julien | Hadoux | Lilly: Consultant; Roche: Consultant; IPSEN: Consultant [xRelationship Ended]; Pharma Mar: Consultant [xRelationship Ended]; AAA: Consultant [xRelationship Ended]. |
| Meredith | Hartley | Autobahn Therapeutics: consultant, Stock Options, Patent Holder |

The following planning committee members and faculty reported relevant financial relationships.

| | | |
|-----------|------------------|---|
| Meredith | Hartley | Autobahn Therapeutics: consultant, Stock Options, Patent Holder |
| James | Hennessey | AbbVie: Clinical Study design and reporting; Allergan Pharma: Clinical Study design; Spetrix Pharma: Clinical Study design; Best Doctors®: Clinical Case Reviews |
| Steven | Hodak | Sonic Healthcare USA: Speaker |
| Mimi | Hu | Blueprint Medicines: Advisory Board [XRelationship Ended]; Eli Lilly & Co: Researcher (site PI for a trial), Steering Committee Member |
| Mimi | Hu | Blueprint Medicines: Advisory Board [XRelationship Ended]; Eli Lilly & Co: Researcher (site PI for a trial), Steering Committee Member |
| Ken-ichi | Ito | Taiho Pharmaceutical Co., Ltd.: Collaborative Research |
| Arnaud | Jannin | HRA Pharma- Presentation 15 min in the French Endocrine Congress 2022 (mitotane toxicities) [x Relationship has ended] |
| Jeffrey | Knauf | Kura Oncology: Royalties |
| Josef | Köhrle | DiaSorin Deutschland GmbH: Speaker Honorarium [xRelationship Ended]. |
| Bhavana | Konda | EISAI: Grant Support to my institution; Merck: Grant Support to my institution; Xencor: Grant Support to my Institution [xRelationship Ended]; Eli Lilly & Co: Grant Support to my institution [xRelationship Ended] |
| Tim | Korevaar | Berlin Chemie: Speaker fee; Merck: Speaker fee; IBSA: Speaker fee; Quidel: Speaker fee |
| Anupam | Kotwal | Horizon Medical Affairs TED advisory Board: Advisor |
| Nancy | Lee | Merck: Consultant; Meck EMD: Consultant |
| Angela | Leung | Vertice Pharma: Consultant [xRelationship Ended]; Ibsa Institut Biochimique: Article processing charges paid for an invited review article [xRelationship Ended]; China Merck: Speaker |
| Angela | Leung | Vertice Pharma: Consultant [xRelationship Ended]; Ibsa Institut Biochimique: Article processing charges paid for an invited review article [xRelationship Ended]; China Merck: Speaker |
| Mark | Lupo | Roche Diagnostics: Research Funding; Takeda: Research Funding; Interpace Diagnostics: Consulting; Horizon Therapeutics: Consulting/Speaking; Abbvie: Consulting/Speaking; Eisai: Consulting/Speaking; Quidel: Research Funding/Speaking |
| Mark | Lupo | Roche Diagnostics: Research Funding; Takeda: Research Funding; Interpace Diagnostics: Consulting; Horizon Therapeutics: Consulting/Speaking; Abbvie: Consulting/Speaking; Eisai: Consulting/Speaking; Quidel: Research Funding/Speaking |
| Markus | Luster | Presider of National Society: Due to my current role as presider of our national society I stopped accepting paid services |
| Jennifer | Mammen | Corny: Stocks; Thermo Fisher: Stocks [xRelationship Ended]; Thyramir: Research Funding |
| Cary | Mariash | Horizon Pharmaceuticals: Consultant; Concepts Therapeutics: Research Principal Investigator |
| Nicole | Massoll | Interpace Diagnostics: Consultant |
| Elizabeth | McAninch | Abbvie:Consultant (\$0 received)[x Relationship Ended];Acella:Consultant (speaking at unbranded ATA product theater);Equilibrate Therapeutics, LLC:Co-founder US patent pending US20210361921A1 Patent owner |

The following planning committee members and faculty reported relevant financial relationships.

| | | |
|-----------|------------------------|---|
| Ann-Elin | Meling Stokland | Novo Nordisk: Invited Speaker |
| Mihaly | Mezei | Zymeworks: Stock Holder |
| Yuri | Nikiforov | University of Pittsburgh: IP ownership and receives royalties related to Thyroseq; Sonic Healthcare, LLC: Consultant |
| Julia | Noel | Pulse Biosciences: Consultant |
| Carmelo | Nucera | MEDACorp: Total 1 hr consultant for rare endocrine diseases [xRelationship Ended] |
| Vasiliki | Pelekanou | BAYER US-Pharmaceuticals: Employee |
| Eyal | Robenshtok | Roche: Speaker Fee, Advisory Board; Neopharm: Speaker Fee; CTS Israel: Speaker Fee, Advisory Board |
| Douglas | Ross | Arbor Pharmaceuticals: consultant; Jnana Therapeutics: consultant [xRelationship Ended]; IBSA Pharma: consultant [xRelationship Ended]; Spectrix Therapeutics: consultant [xRelationship Ended]; Medullary Thyroid Cancer Consortium: Safety monitoring |
| Mario | Salvi | IBSA Switzerland: IBSA Speaker Fee [xRelationship Ended]; Roche Italy: Funding Institutional Research; GSK Italy: Funding Individual Research |
| Michael | Singer | Medtronic: Consultant |
| Julie Ann | Sosa | GlaxoSmith Kline, Novo Nordisk, Astra Zeneca, Eli Lilly: Member, Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry; Exelixis and Eli Lilly: Institutional research funding |
| Julie Ann | Sosa | GlaxoSmith Kline, Novo Nordisk, Astra Zeneca, Eli Lilly: Member, Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry; Exelixis and Eli Lilly: Institutional research funding |
| Julie Ann | Sosa | GlaxoSmith Kline, Novo Nordisk, Astra Zeneca, Eli Lilly: Member, Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry; Exelixis and Eli Lilly: Institutional research funding |
| Christine | Spitzweg | Lilly: Honoraria for Advisory Boards, Lectures; Roche: Honoraria for Advisory Boards, Lecture; Sanofi: Honoraria for Advisory Boards, Lecture; Eisai: Honoraria for Advisory Boards, Lecture; Ipsen: Honoraria for Advisory Boards, Lecture |
| Marius | Stan | Horizon Pharma: Consultant and adviser - funds to Mayo Clinic research; Immunovant Inc: Consultant and adviser - funds to Mayo Clinic; Siemens Inc: Consultant for clinical trials; OrthoClinical Diagnostics: Consultant for clinical trials; Vasaragen: Consultant - funds to Mayo Clinic research [xRelationship Ended]; Tolmar Inc: Consultant for clinical trials [xRelationship Ended] |
| Insoo | Suh | Medtronic: Consultant; Iota Biosciences: Consultant, ownership interest; GLG: Consultant; RPWB, LLC: Consultant; Prescient Surgical: Consultant, ownership interest |
| Matthew | Taylor | Bayer: Advisor/consultant [xRelationship Ended]; Blueprint Medicines: Advisor/consultant, speaker; Bristol Myers Squibb: Advisor/consultant, speaker; Cascade Prodrug: Advisor/consultant; Eisai Inc: Advisor/consultant, speaker; Merck: Advisor/consultant, speaker; Pfizer: Advisor/consultant; Regeneron: Advisor/consultant [xRelationship Ended]; Exelixis: Advisor/consultant; ImmuneOnc: Advisor/consultant; Sanofi/Genzyme: Advisor/consultant |
| Johnson | Thomas | Novo Nordisk: Speaker bureau |
| Johnson | Thomas | Novo Nordisk: Speaker bureau |

The following planning committee members and faculty reported relevant financial relationships.

| | | |
|------------|-------------------|--|
| R. Michael | Tuttle | Elesta: Research funding to our institution |
| R. Michael | Tuttle | Elesta: Research funding to our institution |
| Bijay | Vaidya | Sandoz Speaker: Honorarium [x Relationship ended] Berlin-Chimie: Speaker Honorarium [x Relationship ended] Novo-Nordis: Registration & travel expenses to attend the annual meeting of the European Society of Endocrinology |
| Camilla | Virili | IBSA CH: Meeting honorarium, travel reimbursement |
| Camilla | Virili | IBSA CH: Meeting honorarium, travel reimbursement |
| Jonathan | Wadsley | AstraZeneca: Research funding [xRelationship Ended]; Sanofi Genzyme: Research funding [xRelationship Ended]; Lilly: Consultant, speaker; Roche: Consultant, speaker; Ipsen: Consultant, speaker; Bayer: Consultant, speaker; Eisai: Consultant, speaker; Novartis: Consultant, speaker |
| Steven | Waguespack | Bayer: Consultant/Speaker |
| Jonathan | Wasserman | IPSEN : Consultant [x Relationship Ended] |
| Alison | Woodworth | Diasorin: Speaker [x Relationship Ended] |
| Marina | Nikiforova | University of Pittsburgh: IP ownership and receives royalties related to Thyroseq; Sonic Healthcare, LLC: Consultan |
| William | Ferguson | Abbie: Employee |
| Woody | Sistruck | Abbvie: Speaker [x Relationship ended]; Horizon Therapeutics:Speaker, Advisory Board [x Relationship ended] ; Interpace Diagnostics:Research Support [x Relationship ended] |